Research programme: human papillomavirus infections - MIGENIX

Drug Profile

Research programme: human papillomavirus infections - MIGENIX

Alternative Names: ORI 2000

Latest Information Update: 08 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MIGENIX
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Human papillomavirus infections

Most Recent Events

  • 30 Apr 2006 Discontinued - Preclinical for Human papillomavirus infections in Canada (unspecified route)
  • 22 Sep 2004 Micrologix Biotech is now called MIGENIX
  • 21 Nov 2002 The intellectual property of Origenix Technologies has been acquired by Micrologix Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top